Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRODIN vs BRAVELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) agonist; initially stimulates pituitary gonadotropin release, then downregulates Gn RH receptors, suppressing LH and FSH secretion.
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Treatment of infertility: controlled ovarian hyperstimulation in assisted reproductive technology (ART),Ovulation induction in anovulatory women
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
750 mg intramuscularly twice weekly for 2-3 weeks; or 500 mg intramuscularly once weekly for 4-6 weeks.
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
Terminal elimination half-life is approximately 35 hours (range 28–48 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
Metabolized via peptidases in the liver and kidneys; metabolites are inactive.
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Primarily renal, with approximately 75% of a dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for less than 5% of elimination.
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Approximately 30% bound to plasma proteins, predominantly albumin.
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
Apparent volume of distribution is approximately 0.2 L/kg, indicating limited extravascular distribution and confinement primarily to the extracellular fluid space.
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
Subcutaneous administration: absolute bioavailability is approximately 75–80% due to partial presystemic degradation; intramuscular administration: bioavailability is similar, approximately 70–80%.
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
GFR 10-50 m L/min: reduce dose to 500 mg intramuscularly twice weekly; GFR <10 m L/min: 500 mg intramuscularly once weekly.
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: contraindicated.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Not recommended in pediatric patients; limited safety data available.
Not indicated for use in pediatric patients; safety and efficacy not established.
Use with caution; dose adjustment based on renal function recommended; monitor for neurotoxicity.
Not indicated for use in geriatric patients; safety and efficacy not established.
Ovarian hyperstimulation syndrome (OHSS) and multiple births; increased risk of ovarian neoplasms.
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
Ovarian hyperstimulation syndrome (OHSS), multiple gestation, ovarian torsion, pulmonary embolism, hypersensitivity reactions, and monitoring of ovarian response via ultrasound and estradiol levels.
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
Hypersensitivity to Gn RH or similar compounds, ovarian enlargement or cyst not due to polycystic ovary syndrome (PCOS), undiagnosed vaginal bleeding, primary ovarian failure, estrogen-dependent tumors (e.g., breast cancer), and pregnancy.
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
Avoid all alcoholic beverages and any foods or medications containing alcohol (e.g., vinegar sauces, kombucha, some desserts) during therapy and for 48 hours post-treatment to prevent disulfiram-like reaction. No other significant food interactions.
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
Pregnancy Category X. In first trimester, risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second and third trimester exposure associated with fetal growth restriction, oligohydramnios, and neonatal hypotonia. Avoid throughout pregnancy.
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
No data on M/P ratio. Excretion into breast milk unknown. Due to potential for serious adverse reactions (CNS depression, respiratory depression) in breastfed infants, breastfeeding is contraindicated during therapy and for at least 7 days after last dose.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
Not applicable; drug is contraindicated in pregnancy. No studies on pharmacokinetic changes. Do not dose during pregnancy.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
METRODIN (metronidazole) is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It achieves high concentrations in CNS and bone. Use with caution in patients with Cockayne syndrome due to risk of severe hepatotoxicity. Monitor INR closely in patients on warfarin as metronidazole potentiates anticoagulant effect. Dose adjustment required in severe hepatic impairment (Child-Pugh C).
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
Take exactly as prescribed; do not miss doses. Complete the full course even if you feel better.,Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrup) during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction (nausea, vomiting, headache).,May cause metallic taste, dark urine, or gastrointestinal upset; these are usually harmless.,Inform your doctor if you have a history of liver disease, Cockayne syndrome, or are taking blood thinners (warfarin).,If you experience numbness/tingling in hands/feet, seizures, or confusion, seek medical attention immediately.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRODIN vs BRAVELLE, answered by our medical review team.
METRODIN is a Gonadotropin that works by Gonadotropin-releasing hormone (Gn RH) agonist; initially stimulates pituitary gonadotropin release, then downregulates Gn RH receptors, suppressing LH and FSH secretion.. BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRODIN and BRAVELLE depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRODIN is: 750 mg intramuscularly twice weekly for 2-3 weeks; or 500 mg intramuscularly once weekly for 4-6 weeks.. The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRODIN and BRAVELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRODIN is classified as Category C. Pregnancy Category X. In first trimester, risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second and third tri. BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.